However, published patient-level tumor responses in BRAFV600E-mutant CRC are available from Phase 1b clinical trials testing combinations of vemurafenib + cetuximab,14 the alternate BRAF and MEK inhibitors dabrafenib + trametinib,16 and dabrafenib + trametinib + panitumumab (an EGFRi).19 Under the assumption that the alternate BRAF, MEK, and EGFR inhibitors are clinically equivalent,44, 45 we used the data from these three studies to constrain our simualtions, and predict clinical responses to GDC-0994-containing regimens. Here, MAP2K7 is linked to neoplasm.